Microneedle Patch Delivery to the Skin of Virus-like Particles Containing Heterologous M2e Extracellular Domains of Influenza Virus Induces Broad Heterosubtypic Cross-protection

Overview

Journal J Control Release

Specialty Pharmacology

Date 2015 May 25

PMID 26003039

Citations 22

Authors

Min-Chul Kim

Jeong Woo Lee

Hyo-Jick Choi

Yu-Na Lee

Hye Suk Hwang

Jongsang Lee

Cheol Kim

Jong Seok Lee

Carlo Montemagno

Mark R Prausnitz

Sang-Moo Kang

Affiliations

Soon will be listed here.

Abstract

A broadly cross-protective influenza vaccine that can be administrated by a painless self-immunization method would be a value as a potential universal mass vaccination strategy. This study developed a minimally-invasive microneedle (MN) patch for skin vaccination with virus-like particles containing influenza virus heterologous M2 extracellular (M2e) domains (M2e5x VLPs) as a universal vaccine candidate without adjuvants. The stability of M2e5x VLP-coated microneedles was maintained for 8weeks at room temperature without losing M2e antigenicity and immunogenicity. MN skin immunization induced strong humoral and mucosal M2e antibody responses and conferred cross-protection against heterosubtypic H1N1, H3N2, and H5N1 influenza virus challenges. In addition, M2e5x VLP MN skin vaccination induced T-helper type 1 responses such as IgG2a isotype antibodies and IFN-γ producing cells at higher levels than those by conventional intramuscular injection. These potential immunological and logistic advantages for skin delivery of M2e5x VLP MN vaccines could offer a promising approach to develop an easy-to-administer universal influenza vaccine.

Citing Articles

Vaccine-Induced Immunity Elicited by Microneedle Delivery of Influenza Ectodomain Matrix Protein 2 Virus-like Particle (M2e VLP)-Loaded PLGA Nanoparticles.

Gomes K, Vijayanand S, Bagwe P, Menon I, Kale A, Patil S Int J Mol Sci. 2023; 24(13).

PMID: 37445784 PMC: 10341628. DOI: 10.3390/ijms241310612.

Enhanced Immunogenicity of an Influenza Ectodomain Matrix-2 Protein Virus-like Particle (M2e VLP) Using Polymeric Microparticles for Vaccine Delivery.

Gomes K, Menon I, Bagwe P, Bajaj L, Kang S, DSouza M Viruses. 2022; 14(9).

PMID: 36146733 PMC: 9506217. DOI: 10.3390/v14091920.

Progress towards the Development of a Universal Influenza Vaccine.

Wang W, Sayedahmed E, Sambhara S, Mittal S Viruses. 2022; 14(8).

PMID: 36016306 PMC: 9415875. DOI: 10.3390/v14081684.

Recent Progress in Recombinant Influenza Vaccine Development Toward Heterosubtypic Immune Response.

Carascal M, Pavon R, Rivera W Front Immunol. 2022; 13:878943.

PMID: 35663997 PMC: 9162156. DOI: 10.3389/fimmu.2022.878943.

Transdermal Vaccination with the Matrix-2 Protein Virus-like Particle (M2e VLP) Induces Immunity in Mice against Influenza A Virus.

Braz Gomes K, DSa S, Lovia Allotey-Babington G, Kang S, DSouza M Vaccines (Basel). 2021; 9(11).

PMID: 34835255 PMC: 8619166. DOI: 10.3390/vaccines9111324.

References

Coenen F, Tolboom J, Frijlink H . Stability of influenza sub-unit vaccine. Does a couple of days outside the refrigerator matter?. Vaccine. 2005; 24(4):525-31. DOI: 10.1016/j.vaccine.2005.07.081. View

Kang S, Yoo D, Kim M, Song J, Park M, O E . MyD88 plays an essential role in inducing B cells capable of differentiating into antibody-secreting cells after vaccination. J Virol. 2011; 85(21):11391-400. PMC: 3194946. DOI: 10.1128/JVI.00080-11. View

Huber V, Lynch J, Bucher D, Le J, Metzger D . Fc receptor-mediated phagocytosis makes a significant contribution to clearance of influenza virus infections. J Immunol. 2001; 166(12):7381-8. DOI: 10.4049/jimmunol.166.12.7381. View

Qi H, Egen J, Huang A, Germain R . Extrafollicular activation of lymph node B cells by antigen-bearing dendritic cells. Science. 2006; 312(5780):1672-6. DOI: 10.1126/science.1125703. View

Mozdzanowska K, Feng J, Eid M, Zharikova D, Gerhard W . Enhancement of neutralizing activity of influenza virus-specific antibodies by serum components. Virology. 2006; 352(2):418-26. DOI: 10.1016/j.virol.2006.05.008. View

Gill H, Prausnitz M . Coated microneedles for transdermal delivery. J Control Release. 2006; 117(2):227-37. PMC: 1853346. DOI: 10.1016/j.jconrel.2006.10.017. View

Jayasekera J, Moseman E, Carroll M . Natural antibody and complement mediate neutralization of influenza virus in the absence of prior immunity. J Virol. 2007; 81(7):3487-94. PMC: 1866020. DOI: 10.1128/JVI.02128-06. View

Quan F, Huang C, Compans R, Kang S . Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus. J Virol. 2007; 81(7):3514-24. PMC: 1866067. DOI: 10.1128/JVI.02052-06. View

Pape K, Catron D, Itano A, Jenkins M . The humoral immune response is initiated in lymph nodes by B cells that acquire soluble antigen directly in the follicles. Immunity. 2007; 26(4):491-502. DOI: 10.1016/j.immuni.2007.02.011. View

10.

de Jonge J, Amorij J, Hinrichs W, Wilschut J, Huckriede A, Frijlink H . Inulin sugar glasses preserve the structural integrity and biological activity of influenza virosomes during freeze-drying and storage. Eur J Pharm Sci. 2007; 32(1):33-44. DOI: 10.1016/j.ejps.2007.05.112. View

11.

Quan F, Compans R, Nguyen H, Kang S . Induction of heterosubtypic immunity to influenza virus by intranasal immunization. J Virol. 2007; 82(3):1350-9. PMC: 2224423. DOI: 10.1128/JVI.01615-07. View

12.

Eliasson D, Bakkouri K, Schon K, Ramne A, Festjens E, Lowenadler B . CTA1-M2e-DD: a novel mucosal adjuvant targeted influenza vaccine. Vaccine. 2008; 26(9):1243-52. DOI: 10.1016/j.vaccine.2007.12.027. View

13.

Amorij J, Huckriede A, Wilschut J, Frijlink H, Hinrichs W . Development of stable influenza vaccine powder formulations: challenges and possibilities. Pharm Res. 2008; 25(6):1256-73. PMC: 2346510. DOI: 10.1007/s11095-008-9559-6. View

14.

Gill H, Denson D, Burris B, Prausnitz M . Effect of microneedle design on pain in human volunteers. Clin J Pain. 2008; 24(7):585-94. PMC: 2917250. DOI: 10.1097/AJP.0b013e31816778f9. View

15.

Van Damme P, Oosterhuis-Kafeja F, Van der Wielen M, Almagor Y, Sharon O, Levin Y . Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults. Vaccine. 2008; 27(3):454-9. DOI: 10.1016/j.vaccine.2008.10.077. View

16.

Schotsaert M, De Filette M, Fiers W, Saelens X . Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments. Expert Rev Vaccines. 2009; 8(4):499-508. PMC: 2706389. DOI: 10.1586/erv.09.6. View

17.

Neumann G, Noda T, Kawaoka Y . Emergence and pandemic potential of swine-origin H1N1 influenza virus. Nature. 2009; 459(7249):931-9. PMC: 2873852. DOI: 10.1038/nature08157. View

18.

Smith G, Vijaykrishna D, Bahl J, Lycett S, Worobey M, Pybus O . Origins and evolutionary genomics of the 2009 swine-origin H1N1 influenza A epidemic. Nature. 2009; 459(7250):1122-5. DOI: 10.1038/nature08182. View

19.

Quan F, Kim Y, Yoo D, Compans R, Prausnitz M, Kang S . Stabilization of influenza vaccine enhances protection by microneedle delivery in the mouse skin. PLoS One. 2009; 4(9):e7152. PMC: 2745577. DOI: 10.1371/journal.pone.0007152. View

20.

Chen X, Prow T, Crichton M, Jenkins D, Roberts M, Frazer I . Dry-coated microprojection array patches for targeted delivery of immunotherapeutics to the skin. J Control Release. 2009; 139(3):212-20. DOI: 10.1016/j.jconrel.2009.06.029. View